MedPath

The study of testing effect of syp.Rubyclin in discoloration and itching of ski

Phase 2
Conditions
Health Condition 1: null- Eczema skin disorders redness itching burning
Registration Number
CTRI/2018/03/012718
Lead Sponsor
Aushadhi Bhavan
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

subjects with inflammation redness itching burning in eczema

Exclusion Criteria

Subjects with Diabetes Mellitus Type I and uncontrolled Diabetes Mellitus Type II.Known subjects of abnormal thyroid function.Known cases of Severe/Chronic Hepatic or Renal disease.Known subject of any active malignancy.Subjects giving history of significant cardiovascular event < 12 weeks prior to randomization.Subjects ECG demonstrating any signs of uncontrolled arrhythmia / acute ischemia.Lesions of large surface area.Subjects having known chronic, contagious infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV.Subjects using any other investigational drug within 3 days prior to recruitment.Known hypersensitivity to any of the ingredients used in study drug.Pregnant and Lactating femalesSubjects currently participating in any other Clinical studyAny other medical or surgical condition considered unsuitable for subject participation in the study as per Investigator judgment.Subject having H/O keliod formation following skin injury,severe dermatitis requiring systemic corticosteroids

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To study the effect of syp rubyclin in the eczemabacterial count of infected lesion 10 daysscaling inflammation burning and itching in eczema <br/ ><br>Timepoint: 30 days
Secondary Outcome Measures
NameTimeMethod
Reduction severity of pruritis in eczemaeczema severity grade on IGA scaleTimepoint: 30 days
© Copyright 2025. All Rights Reserved by MedPath